On Dec. 20, Congress passed a sweeping overhaul of the tax code in the form of H.R. 1, the Tax Cuts and Jobs Act. While CLSA did not take a position on the overall legislation, we worked in close collaboration and coordination with BIO and our CLSA member companies to ensure that the Orphan Drug Tax Credit – a meaningful incentive for investment in rare disease therapy innovation – was preserved in the final bill passed by Congress. | READ MORE »
Los Angeles Take Back Legislation Rises Anew In 2018 | READ MORE »
The guide is the perfect accessory for navigating around San Francisco and getting the most out of the week, with insights into JPM Week 2018 concurrent events including Biotech Showcase and RESI, and predictions and advice from JPM Week veterans for conquering healthcare investing’s most impactful week of the year | READ MORE »
Bio-Link Depot Grand Opening in Oakland| READ MORE »
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, LinkedIn, and YouTube.
President’s Corner – CLSA Recognizes World Rare Disease Day, Honors Life Sciences Champions at Back to Session Reception, Helps Lead Efforts that Repealed IPAB; CLSI Hosts Women Executives Dinner, Chooses Spring 2018 FAST Companies; and Upcoming Events
By: Sara Radcliffe
CLSA President & CEO
February 28, 2018
Approximately 1 in 10 Americans – that’s an estimated 3.9 million Californians – are affected by a rare disease or disorder. California research institutions and innovative life sciences companies lead the way in identifying the origins of rare diseases, and developing the tools and therapies needed to detect, diagnose, treat and ultimately cure rare diseases. On Feb. 28, CLSA will participate in World Rare Disease Day by hosting and participating in a series of events and activities in Sacramento, Washington, DC and via social media. Learn more here.
CLSA Recognizes Life Sciences Champions at Back to Session Reception in Sacramento
We were pleased to recognize three Life Sciences Champions – Senator Patricia Bates (R-Laguna Niguel), Assemblymember Rob Bonta (D-Alameda) and Assemblymember Heath Flora (R-Ripon) – at our annual Back to Session reception in Sacramento on Feb. 7, 2018. Our Champions joined us, along with members of the State Legislature, legislative staff, key government officials, and other life sciences leaders for networking and lively conversation at Ella Dining Room in downtown Sacramento. Learn more here.
CLSA Helps Lead Efforts that Repealed IPAB
On Feb. 9, Congress passed and the President signed into law a full and permanent repeal of the Independent Payment Advisory Board (IPAB). Eliminating the IPAB is critical for the continued success of California’s innovative life sciences sector, because the board could have harmed biomedical innovation by reducing incentives for investment in new research and product development. Last year, the California delegation overwhelmingly supported stand-alone legislation, supported by CLSA, to repeal IPAB (H.R. 849). Introduced by California Rep. Raul Ruiz, MD (D-Palm Desert), 30 bipartisan members of the California Congressional Delegation voted in support of the measure when it came to the House Floor. The permanent repeal enacted earlier this month was included as a provision of the 2-year budget deal needed to avoid a government shutdown (H.R. 1892).
Read more here.
CLSA Keynote at Molecular Med Tri-Conference
On Feb. 13, I was pleased to speak at the 2018 Molecular Med Tri-Conference on what it takes to create a thriving life sciences ecosystem – using California as an example and citing statistics from CLSA’s 2018 Life Sciences Industry Report – along with California’s strength in cancer research. Learn more about my keynote and the event in this Bio-IT World article.
Institute Hosts First CLSI Women Executives Dinner
Twenty women executives from established life sciences companies, FAST startups and investment firms joined the California Life Sciences Institute’s first Women Life Sciences Executives Dinner on Feb. 17, 2018 at The Workshop in San Francisco. The highly-acclaimed dinners are designed to foster networking and peer-to-peer exchanges on key industry issues for women executives, and to create valuable connections and champions among women leaders. If you are interested in hosting a Women Life Science Executives Dinner, please contact Lori Lindburg at firstname.lastname@example.org.
Six Companies Selected for FAST Spring 2018
CLSI is pleased to announce the six Spring 2018 FAST companies: Abalone Bio, developing functional antibody therapeutics that block or activate membrane protein using proprietary Functional Antibody Selection Technology platform; Antibiotic Adjuvant, developing AI-empowered decision support delivered at the point of prescription to reduce and prevent antibiotic resistance; Atropos Therapeutics, developing an optimized combination therapy for cancer and novel therapeutics for aging based on cellular senescence; C. Light Technologies, developing an ultra-precision retinal eye-tracking device to empower doctors to detect neurodeficits; Melio, developing a rapid broad-based platform for pathogen profiling for sepsis in newborns; and Valley Fever Solutions, developing a first in class new antifungal to treat valley fever.
CLSA and PwC Launch Drug Commercialization Webinar Series
The drug launch environment is constantly changing in today’s evolving healthcare environment. Join the experts at PwC as they take you through a series of four launch training sessions to discuss the external environment, key considerations, best practices, and capabilities needed for a successful product launch. Learn more here.
BioProcess International West
CLSA will also present information from our 2017 Industry Report in a Keynote at 2:30pm on March 22 at the Hilton San Francisco Union Square. CLSA members can email Membership@califesciences.org to request a 10%.
CLSA Launches Innovation Breakfast Series with Johnson & Johnson Innovation/JLABS
Join Johnson & Johnson Innovation, JLABS and CLSA on March 27, 2018 for an exclusive fireside chat with Dr. Eric Ostertag, founder and CEO of Poseida Therapeutics, Inc. Poseida is advancing several innovative gene editing technologies, including Footprint-Free Gene Editing (FFGE) which is potentially the cleanest gene editing technology that is commercially available today. In this interactive discussion, hear the journey of an entrepreneur whose cutting-edge gene editing science can potentially impact some of today’s biggest health challenges. Register here.
President & Chief Executive Officer
California Life Sciences Association
PS – Do you have newsworthy items to submit for consideration in our monthly CLSA Bulletin? Feel free to send those tips to Elizabeth Gibson, CLSA’s Senior Director of Marketing and Programs (EGibson@califesciences.org).
Congress Passes Tax Reform Legislation, Protecting Critical Orphan, R&D Tax Credits
Dec. 20, 2017
On Dec. 20, Congress passed a sweeping overhaul of the tax code in the form of H.R. 1, the Tax Cuts and Jobs Act. While CLSA did not take a position on the overall legislation, we did work in close collaboration and coordination with BIO and our CLSA member companies to ensure that the Orphan Drug Tax Credit – a meaningful incentive for investment in rare disease therapy innovation – was preserved in the final bill passed by Congress.
The California Congressional Delegation overwhelmingly opposed H.R. 1 when it was brought to the full House and Senate for a vote. In the House, the measures passed by a vote of 224 to 201. All present California Democrats voted against the bill (38 voted no, and Rep. Grace Napolitano (D-El Monte) did not vote) with 2 Republicans, Reps. Darrell Issa (R-Vista) and Dana Rohrabacher (R-Huntington Beach), also voting against the bill. Overall, 12 House Republicans opposed the measure, including the aforementioned 2 from California. No House Democrats voted for the bill. In the Senate, H.R. 1 passed by a vote of 51 to 48. The vote fell along party lines, with all Republicans voting for the measure, and all Democrats voting against it. Both of California’s senators – Sens. Dianne Feinstein (D) and Kamala Harris (D) – opposed the measure. (Sen. John McCain (R-Ariz.) did not vote.)
The bill now goes to the President’s desk for signature, where it is expected to be signed into law before the end of the year.
By way of background, in November, both the House and Senate passed their respective versions of H.R. 1. Notably, the House-passed bill eliminated the Orphan Drug Tax Credit (ODTC). By contrast, the Senate-passed bill retained the ODTC, but at a significantly reduced rate of 27.5% in order to meet the revenue targets necessary to pass comprehensive tax reform. (Note: Section 45C of the Internal Revenue Code currently provides eligible drugmakers a tax credit of 50% of the qualified clinical testing expenses incurred in a taxable year with respect to drugs designated as “orphan drugs” by the FDA.) Neither bill addressed the medical device tax, and both bills retained the R&D tax credit.
Over the past several months, CLSA has advocated vociferously for the Orphan Drug Tax Credit to be retained in the reformed tax code. Most recently, we sent a letter to the only conference committee member from California, Rep. Devin Nunes (R-Visalia), urging that he support the protection of the ODTC in the Conference Report. A copy of the letter we sent to him can be viewed here. CLSA also coordinated a California company sign-on letter to House Majority Leader Kevin McCarthy (R-Bakersfield) urging that the ODTC be included in the final tax reform package. Cosigned by 21 California companies invested in rare disease therapy innovation, a copy of that letter can be viewed here. We are pleased to see that our advocacy and engagement helped ensure the inclusion of a meaningful Orphan Drug Credit in the conference package. Click here to view the legislation.
It is worth noting that the R&D Tax Credit remains intact and was not altered by H.R. 1. Another tax-related provision of interest, the medical device excise tax, was not addressed in H.R. 1. Click here for an update on our efforts to repeal the medical device tax.
Questions? Please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations & Alliance Development (email@example.com).
CLSA Urging Congress to Repeal Medical Device Tax by Year’s End
Dec. 19, 2017
We are pleased to share that on Dec. 18, The Orange County Register published an op-ed from CLSA President & CEO Sara Radcliffe and CLSA Board Chairman Don Bobo (Corporate VP, Strategy & Corporate Development of Edwards Lifesciences), on the need for Congress to repeal the medical device tax. You can view the piece via the CLSA website, OC Register or on Twitter.
This month, Reps. Erik Paulsen (R-Minn.) and Jackie Walorski (R-Ind.) and House Ways & Means Committee Chairman Brady (R-Texas) introduced new legislation to provide a 5-year suspension of the medical device excise tax (H.R. 4617). The current suspension of the 2.3% medical device excise tax expires Dec. 31, 2017, and has not been addressed this year due to healthcare and tax reform packages taking all of the oxygen out of the room.
CLSA, along with our national medtech trade association partners AdvaMed and MDMA, remain committed to a full and permanent repeal of the medical device tax. This bill provides an immediate and long-term reprieve of the tax (which is otherwise set to reactivate in the new year), offering an important intermediary step toward full repeal. CLSA issued a statement on the release of H.R. 4617, supporting the bill and urging swift action before the end of the year. The full statement is available here.
We are hopeful the bill will be advanced prior to year’s end, potentially as part of a government funding bill or Continuing Resolution. CLSA continues to urge our delegation to act on at least a long-term suspension (if not full repeal) before year’s end. Our understanding is that House Leadership has indicated a commitment to address the tax in January, even though they are aware of the significant burden that will be placed on companies having to pay the tax in the interim (the tax will reactivate effective Jan. 1, 2018 and will be paid every two weeks by affected companies). We continue to press on our House delegation members for more urgent action, and at a minimum are asking members to urge leadership to make a public commitment that the tax will be addressed as soon as possible.
Click here to visit CLSA’s Digital Action Center to urge your member of Congress to scrap the medical device tax on innovation. Questions? Please contact Adam Lotspike, CLSA’s Associate Director of Federal Government Relations (firstname.lastname@example.org).
CLSA Hosts End of Year Reception in DC, Celebrating Achievements in Life Sciences
Dec. 16, 2017
On Dec. 6, CLSA hosted our annual End of Year Reception on Capitol Hill in Washington, DC. Over 150 guests attended the reception, including California Reps. Tony Cárdenas (D- San Fernando Valley), Jimmy Panetta (D-Monterey), Jackie Speier (D-South San Francisco), and David Valadao (R-Hanford), and staff from more than half of our California congressional delegation’s offices.
CLSA would like to extend a heartfelt thank you to our sponsors for the generous support and making this event possible again this year:
Abbott, AbbVie, Amgen, Astellas, BioMarin, Celgene, Edwards Lifesciences, EMD Serono, Genentech, Gilead, Hogan Lovells, Horizon Pharma, McDermott+Consulting, Medtronic, Merck, Organogenesis, Retrophin, Shire, Vertex, VWR, W Strategies and BIO.
Click here to view more photos from the event.
Questions? Please contact Jenny Carey, CLSA’s Vice President of Federal Government Relations and Alliance Development (email@example.com).
PhRMA Files Suit to Stop SB 17, New California Reporting Burdens Law
Dec. 15, 2017
On Dec. 8, the Pharmaceutical Research and Manufacturers of America (PhRMA) filed suit in the United States District Court for the Eastern District of California, seeking to have Senate Bill (SB) 17’s manufacturer reporting requirements declared unconstitutional and void.
Under SB 17, manufacturers will be required to provide a 60-day advance notice of any price increase on a drug to all California public agency purchasers, health insurers, and pharmacy benefit managers (PBMs) if that drug’s price has increased 16 percent or more cumulatively over the previous two calendar years, including the current year’s increase.
California’s Office of Statewide Health Planning and Development (OSHPD) recently released its implementation plan for Senate Bill 17 (Hernandez), and the law’s advance notice provisions are set to take effect on January 1, 2018. Additional quarterly reporting by manufacturers to OSHPD would begin on January 1, 2019.
With the lawsuit, PhRMA seeks a permanent injunction from the Court to prevent the State from implementing or enforcing the law’s requirements related to manufacturer reporting and notices.
PhRMA’s complaint in the case states three central claims. First, SB 17 violates the Commerce Clause, which prohibits California from regulating out-of-state drug pricing. Second, it also violates the First Amendment by “compelling speech by manufacturers justifying their price changes.” Finally, it violates the Fourteenth Amendment’s due process clause on account of unconstitutionally vague language. A copy of the Complaint is available here.
Much of the attention has been paid to the alleged violations of the Commerce Clause, which generally has been interpreted by the United States Supreme Court to prohibit direct regulation of interstate commerce by a state. Thus, a central issue for the Court in the case going forward will be whether a 60-day advance notice of a change in a national list price is direct or incidental regulation of interstate commerce. PhRMA’s complaint argues it is direct regulation because, among other things, the notice effectively “imposes a 60-day nationwide ban on price increases,” which is analogous to other laws previously struck down by the Supreme Court.
CLSA and our industry partners will continue to engage the state regarding SB 17 implementation. As we continue to analyze the potential impacts of implementation on our industry, any members who would like further information on SB 17 or any other new California laws are encouraged to reach out to Oliver Rocroi, CLSA’s Senior Director, State Government Relations (firstname.lastname@example.org) or Brett Johnson, CLSA’s Senior Director, Policy & Regulatory Affairs (email@example.com).
Los Angeles Take Back Legislation Rises Anew in 2018
Dec. 14, 2017
After a relatively quiet year in the County of Los Angeles regarding proposed take back legislation, activity has begun to percolate this month. In December, the expected leadership change from Supervisor Mark Ridley-Thomas to Supervisor Sheila Kuehl as President of the Board for 2018 took place which foreshadows a potentially more aggressive Board in putting the issue on the County’s agenda.
The County Public Health Department released a report in mid-December evaluating the potential take back ordinance. The document gives an overview of the policy proposed, the status and implementation of other local ordinances over the last several years, comments from outside technical experts, concerns with the May 2017 California State Auditor’s Report, and recommendations to move forward with the ordinance.
This report has been sent to each of the Supervisors. While it is currently not on the agenda for any upcoming Board hearings, we do expect newly installed President Sheila Kuehl to move quickly on the item. There is also expectation the County’s EPR Working Group, which previously handled all items related to the legislation, will contact the stakeholders again soon as the County prepares its next steps forward in the new year.
CLSA has been at the forefront of this issue in Los Angeles ever since the County’s early stakeholder meetings held in 2015. CLSA has continued its coalition work with national organizations to collectively organize around the ongoing legislative, political, educational, and other activities on take back in Los Angeles. The coalition meets weekly to share information, discuss strategy, and consider industry comments. Throughout 2017, while the legislation was not directly before the Board, the coalition has worked on opportunities for further educational outreach to the Members, the larger community, and through organizing take back events to show that the legislation is not necessary.
For more information on the proposed legislation, CLSA’s on-the-ground initiatives in Los Angeles, the coalition’s plans, or any questions, please contact Reese Isbell, CLSA’s Director of Local Government and Community Relations (firstname.lastname@example.org).
CLSA Hosts Congressional Briefing, Publishes Report to Raise Awareness of IBD
Dec. 13, 2017
During Crohn’s and Colitis Awareness Week – recognized annually in the U.S. between Dec. 1-7, CLSA hosted a congressional briefing on Dec. 6, in collaboration with Takeda Pharmaceuticals USA, on “Enhancing Patient Access to Therapies for Inflammatory Bowel Disease (IBD).”
More than 3 million Americans suffer from Inflammatory Bowel Disease (IBD),an umbrella term for two distinct conditions – Crohn’s disease and ulcerative colitis – both characterized by chronic inflammation of the gastrointestinal tract. IBD can significantly affect a patient’s quality of life and may impose tremendous public health burdens, including economic costs. There is currently no cure for IBD, and patients require chronic, long-term treatment. Major scientific advances within the fields of genetics, immunology, and microbiology have led to a greater understanding of the underlying mechanisms involved in IBD and an increase in the number of treatment options available for IBD patients.
CLSA’s informational briefing was an opportunity to for Members of Congress, their staff, and other stakeholders to hear from the patient’s perspective (Kate Detwiler – IBD Patient), issues that clinicians face in treating patients (Dr. Michael Weinstein – Gastroenterologist), and how Congress can help to improve access to necessary treatments (Laura Wingate – Crohn’s & Colitis Foundation, and Uthra Sundaram – Takeda Pharmaceuticals USA). The briefing also featured remarks from Reps. Raul Ruiz, MD (D-Palm Desert) and Brad Wenstrup, MD (R-Ohio), who serve as cosponsors of H.R. 2077, Restoring the Patients’ Voice Act, and from Rep. Ryan Costello (R-Pennsylvania), co-chair of the Crohn’s & Colitis Caucus.
To learn more about IBD and how Congress can help ensure patients receive access to necessary therapies, please check out our latest educational brochure, “Understanding IBD.” Questions? Please contact Adam Lotspike, CLSA’s Associate Director of Federal Government Relations (email@example.com).
California Life Sciences Association Invites You To the 2018 S.T.E.M. Olympics
California Life Sciences Association Invites You To the 2018 S.T.E.M. Olympics
Matching Intelligence with Good Times for A Great Cause
La Jolla, California – February 2, 2018 – Bright minds with big hearts and a flare for fun are invited to compete in the First Annual S.T.E.M. Olympics, slated for Wednesday evening, May 2, 5:30 p.m. – 8:30 p.m., at the Nobel Athletic Field near University Town Center complex. The after-hours fun will blend four intellectual matches related to Science, Technology, Engineering and Math with four physical match ups to be completed between each intellectual challenge. Bragging rights and official 2018 S.T.E.M. Champion medals will be given to the first team to finish all eight activities.
“This is going to become one of the best after hours get togethers for young professionals in the Life Sciences and tech-sector firms in the area”, offered Andrew Johnson, the Society’s Community Development Manager. “The idea is to combine intellectual challenges with some pretty fun physical challenges – like a cornhole competition”.
The California Life Sciences Association was quick to sign on as Sponsor and participant. Sponsors, S.T.E.M. teams, cornhole teams, and participants at the 2018 S.T.E.M. Olympics and Cornhole Championships are helping the American Cancer Society to continue to fund vital research and provide programs and services to cancer patients and their families here in San Diego.
The American Cancer Society currently has $7.1 Million in research funded in institutions in San Diego over 16 grants. Beyond San Diego, the Society currently has a total $390 Million in funding over 728 grants throughout the country, making the American Cancer Society the largest, non-governmental, nonprofit funder of cancer research in the United States. The 2018 S.T.E.M. Olympics organizers have set a goal of $163,500 to support additional San Diego grants that are as yet unfunded.
Sam Assmann, Director for Business Development at California Life Sciences became a founding member of the S.T.E.M. Olympics social fete. “We invite every young professional in the area to enjoy an evening of lighthearted competition with the purpose of having a real impact in the fight against cancer. Please join us, and spread the word!”
Interested readers are asked to visit https://goo.gl/CpTz9a for event updates and registering information.
# # #
Protocols.io Offers Free Access to Private Groups to CLSA Members
Protocols.io is a web and mobile platform for organizing, sharing, and keeping research methods up-to-date. It enables R&D teams to keep their protocols safe in one single place and to collaborate on method development and protocol optimization, within their private groups.
Your CLSA membership gives you access to all the benefits and resources of private groups on protocols.io, for one year.
Learn more here: CLSA partnership brochure outlines
HATCH Breaks Ground in the LA BioScience HUB
It’s All Happening… Thanks to You!
HATCH Breaks Ground
After 18 months of planning, designing, networking and studying the needs of the Bioscience industry, HATCH has started construction…
We have been honored to meet and collaborate with brilliant and dedicated stakeholders that make up the Bioscience ecosystem in the Greater Los Angeles area and have been inspired by your shared vision. We feel fortunate to be part of the collective efforts at a time when confluent ideas and interests for the industry have become so apparent.
Because of you, Los Angeles County is home to 20% of all life science employment in California. Because of you, Los Angeles County is home to 6 of the top 20 life science organizations, together generating over $760 million in NIH funding. Because of you, over 70,000 high wage life science jobs generated over $40 billion in economic output last year in Los Angeles County.
We look forward to continuing to work together to bring our shared vision to reality. Stay tuned, there’s plenty more to come!
For more information, please visit: http://labiosciencehub.org/hatch/
FAST, Fellow and CARB-X Updates February 2018
FAST & Fellows Round-Up
- Inflammatix (FAST Fall 2017) announced findings from a new study published in Nature Communications that suggests sepsis can be detected by measuring the immune system Read More
- Read interview with SciBac’s (FAST Fall 2016) CEO, Chief Science Officer and Co-Founder, Jeanette Mucha, who is designing live biotherapeutics to treat and prevent antibiotic resistant disease in the microbiome. Read More
- Ligandal (FAST Spring 2016) unveils nanotech delivery for genetic therapies: What Good Would Amazon Be Without the Shipping? Read More
- GigaGen (FAST Spring 2015) announced moving into new office space in South San Francisco to accommodate the company’s expanding research and development activities for 2018 and beyond. Read More
- Powered by CARB-X company, Entasis Therapeutics ranked highest among biotech companies in their contributions toward stewardship. Read More
- Powered by CARB-X company, BugWorks’ is using advanced mathematical models and algorithms to design appropriate chemical compounds to attack resistant bacteria. Read More about their approach and other ‘Big Data’ techniques for antibiotic discovery.
- Powered By CARB-X company, Debiopharm Group announced an investment in antibiotic development with acquisition of ABAC Therapeutics. Read More
Female Students and Women Professionals Network to Inspire Science Careers
Twenty female students from San Francisco high schools and community college networked with female industry professionals at an event coordinated by CLSI, Young Women in Bio, San Francisco Unified School District (SFUSD) and City College of San Francisco (CCSF). The Speed Networking event, held at Wallenberg High School in San Francisco, allowed female students the opportunity to directly interact with women professionals from BioMarin, Genentech, Nektar, UCSF and more. In addition to being exposed to a diverse set of career roles and career stories, the students got to practice presenting their own experience and interests, and to hone the valuable skill of networking.
Kayla Ko, a junior at Wallenberg high school stated that she valued “getting to know more about the many different fields and pathways that are available.” Her peer, Meron Andebrhan, added “It was so inspiring to see scientists who look like us. I feel like we are changing the world one by one.” Stephany Reeves, a Clinical Manufacturing Associate at BioMarin, when asked why she volunteered for the event, stated: “I can relate to girls who are not sure of what they want to do, and I know how effective it can be to meet and talk to someone like me. I was in the same position, and these opportunities to meet people from industry were so helpful to me.”
Kioma Palkhivata, a Data Analyst at Genentech added, “I was really impressed at how much thought these young women were giving to what they want to do. I let them know that it’s ok if that changes, just be comfortable with who you are and about asking for help to get where you want to go.”
Young Women In Bio (YWIB), part of Women In Bio, is an inspiring program that organizes science events for young women, introducing them to careers in science, technology, engineering, and math.
Institute Hosts First CLSI Women Life Sciences Executives Dinner
The California Life Sciences Institute hosted its first Women Life Sciences Executives Dinner on Thursday February 17 at The Workshop in San Francisco with renown Chef Nikole Krasinski of State Bird Provisions. Twenty women executives from established life science companies, FAST startups and investment firms participated in the dinner, which included a lively and substantive discussion on the topic of “Overcoming Unconscious Bias.” Gunderson Dettmer was the evening’s generous sponsor.
The highly-acclaimed dinners are designed to foster networking and peer-to-peer exchanges on key industry issues for women executives, and to create valuable connections and champions among women leaders.
If you are interested in hosting a future CLSI Women Executives Dinner, please contact Lori Lindburg at firstname.lastname@example.org.
Introducing the Spring 2018 FAST Companies
Six life science startups, vetted and selected by a distinguished review panel, have been selected for CLSI’s Spring 2018 Fellows All-Star Team (FAST) Advisory Program. The Spring 2018 FAST companies are: Abalone Bio, developing functional antibody therapeutics that block or activate membrane protein using proprietary Functional Antibody Selection Technology platform; Antibiotic Adjuvant, developing AI-empowered decision support delivered at the point of prescription to reduce and prevent antibiotic resistance; Atropos Therapeutics, developing an optimized combination therapy for cancer and novel therapeutics for aging based on cellular senescence; C. Light Technologies, developing an ultra-precision retinal eye-tracking device to empower doctors to detect neurodeficits; Melio, developing a rapid broad-based platform for pathogen profiling for sepsis in newborns; Valley Fever Solutions, developing a first in class new antifungal to treat valley fever.
Each company founder will be paired with a team of 10 to 12 advisors who will meet with them over 12 weeks for one-hour advisory sessions. These meetings culminate in a final FAST Showcase in June to a broad audience of industry professionals, entrepreneurs and potential investors.
Halfway through its fifth year, FAST was developed to help some of the most innovative young life science companies FAST-track their way to funding and success. FAST’s 50 company graduates have received over 5500 advisory hours valued at over $1,200,000, have collectively raised $317 million and created 240 new jobs since their participation in FAST.
The FAST program draws on a high-level team of serial entrepreneurs, researchers, investors and business advisors with expertise in clinical development, regulatory, reimbursement, relevant technical R&D, finance, marketing and business development. The teams provide FAST entrepreneurs with intensive team review and coaching to perfect their business model and develop a compelling commercialization strategy.